Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 201–300 of 4,628
Interstitial Lung Abnormalities: State of the Art
Hata, A., Schiebler, M. L., Lynch, D. A., & Hatabu, H. (2021) · Radiology · doi:10.1148/radiol.2021204367 · Cited by 160
Averyanov, A., Koroleva, I., Konoplyannikov, M., Revkova, V., Lesnyak, V., Kalsin, V., Danilevskaya, O., Nikitin, A., Sotnikova, A., Kotova, S., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0037 · Cited by 158
“2%).(4,10) Thus, for the first time, we performed a study of the effects of MSCs transplantation in patients with IPF with the most aggressive course of the disease and the poorest prognosis.”
BackgroundMethodClinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Dempsey, T. M., Sangaralingham, L. R., Yao, X., Sanghavi, D., Shah, N. D., & Limper, A. H. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0456oc · Cited by 156
Heparanase and the hallmarks of cancer
Jayatilleke, K. M., & Hulett, M. D. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02624-1 · Cited by 181
Williamson, J. D., Sadofsky, L. R., & Hart, S. P. (2014) · Experimental Lung Research · doi:10.3109/01902148.2014.979516 · Cited by 174
Hecker, L. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00275.2017 · Cited by 153
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity
Cui, L., Chen, S.-Y., Lerbs, T., Lee, J.-W., Domizi, P., Gordon, S., Kim, Y.-H., Nolan, G., Betancur, P., & Wernig, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16466-4 · Cited by 153
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00165-x · Cited by 152
Costabel, U., Miyazaki, Y., Pardo, A., Koschel, D., Bonella, F., Spagnolo, P., Guzman, J., Ryerson, C. J., & Selman, M. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0191-z · Cited by 163
Self-citationLung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-139 · Cited by 151
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70232-2 · Cited by 150
Self-citationPharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 148
Kenmotsu, H., Wakuda, K., Mori, K. P., Kato, T., Sugawara, S., Kirita, K., Yoneshima, Y., Azuma, K., Nishino, K., Teraoka, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.006 · Cited by 167
Mechanisms of Lung Fibrosis Resolution
Glasser, S. W., Hagood, J. S., Wong, S. S., Taype, C. A., Madala, S. K., & Hardie, W. D. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.018 · Cited by 159
Zinellu, A., Collu, C., Nasser, M., Paliogiannis, P., Mellino, S., Zinellu, E., Traclet, J., Ahmad, K., Mangoni, A. A., Carru, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184134 · Cited by 193
Self-citationBlood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Liu, Y.-M., Nepali, K., & Liou, J.-P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00935 · Cited by 147
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Self-citationInvolvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis
Kobayashi, K., Araya, J., Minagawa, S., Hara, H., Saito, N., Kadota, T., Sato, N., Yoshida, M., Tsubouchi, K., Kurita, Y., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600265 · Cited by 145
European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
Bonella, F., Wijsenbeek, M., Molina-Molina, M., Duck, A., Mele, R., Geissler, K., & Wuyts, W. (2016) · European Respiratory Journal · doi:10.1183/13993003.01204-2015 · Cited by 144
Risk factors for diagnostic delay in idiopathic pulmonary fibrosis
Hoyer, N., Prior, T. S., Bendstrup, E. M., Wilcke, T., & Shaker, S. B. (2019) · Respiratory Research · doi:10.1186/s12931-019-1076-0 · Cited by 155
Developments in lung transplantation over the past decade
van der Mark, S. C., Hoek, R. A. S., & Hellemons, M. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0132-2019 · Cited by 167
Raghu, G., Pellegrini, C. A., Yow, E., Flaherty, K. R., Meyer, K., Noth, I., Scholand, M. B., Cello, J., Ho, L. A., Pipavath, S., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30301-1 · Cited by 144
Self-citationAlsafadi, H. N., Uhl, F. E., Pineda, R., Bailey, K. E., Rojas, M. M., Wagner, D. E., & Königshoff, M. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0276tr · Cited by 160
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Spagnolo, P., Ryerson, C. J., Putman, R. K., Oldham, J. M., Salisbury, M. L., Sverzellati, N., Valenzuela, C., Guler, S. A., Jones, S., Wijsenbeek, M. S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00017-5 · Cited by 163
Self-citationMechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 161
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Lukey, P. T., Harrison, S. A., Yang, S., Man, Y., Holman, B. F., Rashidnasab, A., Azzopardi, G., Grayer, M., Simpson, J. K., Bareille, P., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01992-2018 · Cited by 143
“It is worth noting that AEs related to the gastro-intestinal tract are observed in IPF subjects treated with pirfenidone [3] and nintedanib [2].”
BackgroundRole and New Insights of Pirfenidone in Fibrotic Diseases
Mora, D. A. L.-D. L., Sanchez-Roque, C., Montoya-Buelna, M., Sanchez-Enriquez, S., Lucano-Landeros, S., Macias-Barragan, J., & Armendariz-Borunda, J. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11579 · Cited by 142
Jablonski, R. P., Kim, S., Cheresh, P., Williams, D. B., Morales‐Nebreda, L., Cheng, Y., Yeldandi, A., Bhorade, S., Pardo, A., Selman, M., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201601077r · Cited by 142
Self-citationSafety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Flaherty, K. R., Fell, C. D., Huggins, J. T., Nunes, H., Sussman, R., Valenzuela, C., Petzinger, U., Stauffer, J. L., Gilberg, F., Bengus, M., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00230-2018 · Cited by 141
Self-citationAcute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Collard, H. R., Richeldi, L., Kim, D. S., Taniguchi, H., Tschoepe, I., Luisetti, M., Roman, J., Tino, G., Schlenker-Herceg, R., Hallmann, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01339-2016 · Cited by 138
Self-citationKeloid disorder: Fibroblast differentiation and gene expression profile in fibrotic skin diseases
Macarak, E. J., Wermuth, P. J., Rosenbloom, J., & Uitto, J. (2021) · Experimental Dermatology · doi:10.1111/exd.14243 · Cited by 139
Kim, S. Y., Diggans, J., Pankratz, D., Huang, J., Pagan, M., Sindy, N., Tom, E., Anderson, J. D., Choi, Y., Lynch, D. A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00140-x · Cited by 148
Self-citationVEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
Barratt, S. L., Flower, V., Pauling, J. D., & Millar, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051269 · Cited by 146
Lehmann, M., Buhl, L., Alsafadi, H. N., Klee, S., Hermann, S., Mutze, K., Ota, C., Lindner, M., Behr, J., Hilgendorff, A., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0876-y · Cited by 138
“To date, Nintedanib and Pirfenidone are the only approved drugs known to decelerate disease progression [14, 15].”
Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes
Sauleda, J., Núñez, B., Sala, E., & Soriano, J. B. (2018) · Medical Sciences · doi:10.3390/medsci6040110 · Cited by 137
“Nintedanib, a tyrosine kinase inhibitor that targets growth factor pathways, and pirfenidone, a pleiotropic drug with anti-inflammatory and antifibrotic effects, slow the rate of forced vital capacity (FVC) decline by approximately 50% over the course of one year [51,52] and have shown a reduction in mortality [53,54].”
BackgroundFibrotic microtissue array to predict anti-fibrosis drug efficacy
Asmani, M., Velumani, S., Li, Y., Wawrzyniak, N., Hsia, I., Chen, Z., Hinz, B., & Zhao, R. (2018) · Nature Communications · doi:10.1038/s41467-018-04336-z · Cited by 137
Ghebremariam, Y. T., Cooke, J. P., Gerhart, W., Griego, C., Brower, J., Doyle‐Eisele, M., Moeller, B. C., Zhou, Q., Ho, L. A., de Andrade, J. A., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0614-x · Cited by 147
Self-citationTargeting collagen for diagnostic imaging and therapeutic delivery
Wahyudi, H., Reynolds, A. A., Li, Y., Owen, S. C., & Yu, S. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.007 · Cited by 134
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Collins, B. F., & Raghu, G. (2019) · European Respiratory Review · doi:10.1183/16000617.0022-2019 · Cited by 134
Self-citationNLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis
Tian, R., Zhu, Y., Yao, J., Meng, X., Wang, J., Xie, H., & Wang, R. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.028 · Cited by 134
Behr, J., Nathan, S. D., Wuyts, W. A., Mogulkoc Bishop, N., Bouros, D. E., Antoniou, K., Guiot, J., Kramer, M. R., Kirchgaessler, K.-U., Bengus, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30356-8 · Cited by 134
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Michalski, J. E., Kurche, J. S., & Schwartz, D. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.09.001 · Cited by 145
Effects of nintedanib on the microvascular architecture in a lung fibrosis model
Ackermann, M., Kim, Y. O., Wagner, W. L., Schuppan, D., Valenzuela, C. D., Mentzer, S. J., Kreuz, S., Stiller, D., Wollin, L., & Konerding, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9543-z · Cited by 133
Pan, L., Cheng, Y., Yang, W., Wu, X., Zhu, H., Hu, M., Zhang, Y., & Zhang, M. (2023) · Inflammation · doi:10.1007/s10753-023-01825-2 · Cited by 157
Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-β
Yin, X., Choudhury, M., Kang, J. H., Schaefbauer, K. J., Jung, M.-Y., Andrianifahanana, M., Hernandez, D. M., & Leof, E. B. (2019) · Science Signaling · doi:10.1126/scisignal.aax4067 · Cited by 142
“This is of particular relevance for diseases such as IPF because, although drugs such as nintedanib and pirfenidone have been approved, disease progression with poor longterm prognosis is still the norm for most patients (10, 59, 60), and attempts to identify novel therapeutics are ongoing (61, 62).”
BackgroundJohn, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18397-6 · Cited by 131
Therapeutic targets in idiopathic pulmonary fibrosis
Kolb, M. R. J., Bonella, F., & Wollin, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.062 · Cited by 142
Self-citationHome Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial
Moor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Chavannes, N. H., & Wijsenbeek, M. S. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0328oc · Cited by 147
Helsten, T. L., Schwaederle, M. C., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9579-8 · Cited by 135
Dysregulation of metabolic pathways in pulmonary fibrosis
Rajesh, R., Atallah, R., & Bärnthaler, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108436 · Cited by 139
A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis
Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0784oc · Cited by 129
Self-citationMesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review
Srour, N., & Thébaud, B. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0121 · Cited by 136
Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment
Kaur, A., Mathai, S. K., & Schwartz, D. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00154 · Cited by 129
Kafaja, S., Clements, P. J., Wilhalme, H. M., Tseng, C., Furst, D. E., Kim, G. H. J., Goldin, J. G., Volkmann, E. R., Roth, M. D., Tashkin, D. P., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1845oc · Cited by 135
The controversial role of mast cells in fibrosis
Bradding, P., & Pejler, G. (2018) · Immunological Reviews · doi:10.1111/imr.12626 · Cited by 129
Lin, H., & Jiang, S. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.04.17 · Cited by 133
Molecular imaging of fibrosis: recent advances and future directions
Montesi, S. B., Désogère, P., Fuchs, B. C., & Caravan, P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122132 · Cited by 127
“In IPF, recently conducted clinical trials have used change in forced vital capacity at 52 weeks as the primary outcome (6, 7).”
BackgroundMethodComorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0044-2019 · Cited by 139
Brownell, R., Moua, T., Henry, T. S., Elicker, B. M., White, D., Vittinghoff, E., Jones, K. D., Urisman, A., Aravena, C., Johannson, K. A., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209671 · Cited by 127
Self-citationFragoulis, G., Nikiphorou, E., Larsen, J., Korsten, P., & Conway, R. P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00238 · Cited by 150
Fan, M.-H., Zhu, Q., Li, H., Ra, H.-J., Majumdar, S., Gulick, D. L., Jerome, J. A., Madsen, D. H., Christofidou‐Solomidou, M., Speicher, D. W., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.701433 · Cited by 134
West Japan Oncology Group, Iwata, T., Yoshino, I., Yoshida, S., Ikeda, N., Tsuboi, M., Asato, Y., Katakami, N., Sakamoto, K., Yamashita, Y., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0398-4 · Cited by 125
Self-citationJNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
van der Velden, J. L. J., Ye, Y., Nolin, J. D., Hoffman, S. M., Chapman, D. G., Lahue, K. G., Abdalla, S., Chen, P., Liu, Y., Bennett, B., et al. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0117-2 · Cited by 125
Lung Pericytes and Resident Fibroblasts
Barron, L., Gharib, S. A., & Duffield, J. S. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.07.004 · Cited by 143
Rajala, K., Lehto, J. T., Sutinen, E., Kautiainen, H., Myllärniemi, M., & Saarto, T. (2017) · ERJ Open Research · doi:10.1183/23120541.00084-2017 · Cited by 133
Pérez-Bogerd, S., Wuyts, W. A., Barbier, V., Demeyer, H., Muylem, A. V., Janssens, W., & Troosters, T. (2018) · Respiratory Research · doi:10.1186/s12931-018-0884-y · Cited by 143
Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis
Kropski, J. A., & Blackwell, T. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041317-102715 · Cited by 137
Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1020-3 · Cited by 125
Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis
Brown, S.-A. W., Dobelle, M., Padilla, M. L., Agovino, M., Wisnivesky, J. P., Hashim, D., & Boffetta, P. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201807-481oc · Cited by 149
Lung Manifestations in the Rheumatic Diseases
Doyle, T. J., & Dellaripa, P. F. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.05.015 · Cited by 133
Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study
Verleden, S. E., Tanabe, N., McDonough, J. E., Vasilescu, D. M., Xu, F., Wuyts, W. A., Piloni, D., Sadeleer, L. D., Willems, S., Mai, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30356-x · Cited by 138
Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis
MacKenzie, B., Korfei, M., Henneke, I., Sibinska, Z., Xia, T., Hezel, S., Dilai, S., Wasnick, R. M., Schneider, B., Wilhelm, J., et al. (2015) · Respiratory Research · doi:10.1186/s12931-015-0242-2 · Cited by 124
Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., et al. (2017) · Respirology · doi:10.1111/resp.12989 · Cited by 123
Idiopathic pulmonary fibrosis: An update
Spagnolo, P., Sverzellati, N., Rossi, G., Cavazza, A., Tzouvelekis, A., Crestani, B., & Vancheri, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.982165 · Cited by 120
Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis
Yan, Y., Ma, L., Zhou, X., Ponnusamy, M., Tang, J., Zhuang, M. A., Tolbert, E., Bayliss, G., Bai, J., & Zhuang, S. (2016) · Kidney International · doi:10.1038/ki.2015.293 · Cited by 121
Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., López-Otín, C., & Pardo, A. (2016) · European Respiratory Journal · doi:10.1183/13993003.00398-2016 · Cited by 122
Self-citationZhang, Y., Lu, W., Zhang, X., Lü, J., Xu, S., Chen, S., Zhong, Z., Zhou, T., Wang, Q., Chen, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104307 · Cited by 129
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Inoue, Y., Richeldi, L., Walsh, S. L. F., Kolb, M. R. J., Koschel, D., Moua, T., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04538-2020 · Cited by 159
Self-citationZhang, C., Wu, Z., Li, J., Tan, K., Yang, W., Zhao, H., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26634 · Cited by 131
Valenzi, E., Tabib, T., Papazoglou, A., Sembrat, J., Trejo Bittar, H. E., Rojas, M., & Lafyatis, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.595811 · Cited by 121
Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Zheng, Q., Cox, I. A., Campbell, J. A., Xia, Q., Otáhal, P., de Graaff, B., Corte, T. J., Teoh, A. K. Y., Walters, E. H., & Palmer, A. J. (2022) · ERJ Open Research · doi:10.1183/23120541.00591-2021 · Cited by 148
Matteson, E. L., Kelly, C. A., Distler, J. H. W., Hoffmann‐Vold, A., Seibold, J. R., Mittoo, S., Dellaripa, P. F., Aringer, M., Pope, J. E., Distler, O., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42075 · Cited by 148
Self-citationDinnon, K. H., Leist, S. R., Okuda, K., Dang, H., Fritch, E. J., Gully, K. L., la Cruz, G. D., Evangelista, M. D., Asakura, T., Gilmore, R. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5070 · Cited by 149
Cigarette Smoke-Induced Respiratory Response: Insights into Cellular Processes and Biomarkers
Cha, S.-R., Jang, J., Park, S., Ryu, S. M., Cho, S.-J., & Yang, S. (2023) · Antioxidants · doi:10.3390/antiox12061210 · Cited by 163
Behr, J., Neuser, P., Prasse, A., Kreuter, M., Rabe, K., Schade-Brittinger, C., Wagner, J., & Günther, A. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0462-y · Cited by 120
Reducing protein oxidation reverses lung fibrosis
Anathy, V., Lahue, K. G., Chapman, D. G., Chia, S. B., Casey, D. T., Aboushousha, R., van der Velden, J. L. J., Elko, E., Hoffman, S. M., McMillan, D. H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0090-y · Cited by 120
Self-citationCecchini, M. J., Hosein, K., Howlett, C. J., JOSEPH, M. G., & Mura, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0857-1 · Cited by 141
Japanese guideline for the treatment of idiopathic pulmonary fibrosis
Homma, S. A., Bando, M., Azuma, A., Sakamoto, S., Sugino, K., Ishii, Y., Izumi, S., Inase, N., Inoue, Y., Ebina, M., et al. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.003 · Cited by 135
Self-citationAdvances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Liu, G. Y., Budinger, G. R. S., & Dematte, J. E. (2022) · BMJ · doi:10.1136/bmj-2021-066354 · Cited by 145
Wuyts, W. A., Kolb, M., Stowasser, S., Stansen, W., Huggins, J. T., & Raghu, G. (2016) · Lung · doi:10.1007/s00408-016-9912-1 · Cited by 119
Self-citationBetensley, A., Sharif, R., & Karamichos, D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm6010002 · Cited by 119
Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial
Brody, S. L., Gunsten, S. P., Luehmann, H. P., Sultan, D. H., Hoelscher, M., Heo, G. S., Pan, J., Koenitzer, J. R., Lee, E. C., Huang, T., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1132oc · Cited by 125
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 128
Self-citationTissue remodelling in pulmonary fibrosis
Knudsen, L., Ruppert, C., & Ochs, M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2543-2 · Cited by 129
The Future of Lung Transplantation
Young, K. A., & Dilling, D. F. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1036 · Cited by 140
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
Kreuter, M., Polke, M., Walsh, S. L. F., Krisam, J., Collard, H. R., Chaudhuri, N., Avdeev, S. N., Behr, J., Calligaro, G., Corte, T. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01760-2019 · Cited by 128
“Controlled trials suggest that nintedanib may prolong the time to the first AEIPF(26), while post-hoc data on pirfenidone suggest that it may reduce the risk for respiratory related hospitalisation.”
BackgroundSelf-citationMyllärniemi, M., & Kaarteenaho, R. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26385 · Cited by 117
Ahmadi, Z., Wysham, N. G., Lundström, S., Janson, C., Currow, D. C., & Ekström, M. P. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207439 · Cited by 121
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.